To determine the effectiveness of amitriptyline compared to placebo in the management of moderate to severe HIV related peripheral neuropathy.

Submission date 06/11/2014	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 17/11/2014	Overall study status Completed	 Statistical analysis plan [X] Results
Last Edited 15/05/2015	Condition category Nervous System Diseases	Individual participant data

Plain English summary of protocol

Background and study aims

The peripheral nervous system is part of the nervous system that is made up of the nerves and ganglia (group of nerve cells) outside of the brain and spinal cord (the central nervous system). It connects the central nervous system to the limbs and organs of the body. Damage to peripheral nerves, especially the long nerves of the feet and hands, is common in people infected with HIV. This damage may be caused by the virus itself, some of the antiretrioviral drugs used to treat HIV /AIDS, or as a result of opportunistic infections, for example thrush, herpes and tuberculosis. The nerve damage is often painful, can have a detrimental effect on a person's quality of life and has significant socioeconomic effects. Unlike other types of peripheral neuropathy (e.g., the neuropathy that develops in people with diabetes mellitus), there are, as yet, no effective treatments for painful HIV neuropathy. Here, we want to see if amitriptyline, an antidepressant drug that has been shown to relieve pain in other types of neuropathy, can provide pain relief better than that of a placebo (a dummy pill) in patients with painful HIV neuropathy.

Who can participate?

Adult HIV-infected individuals that have been diagnosed with painful HIV-associated sensory neuropathy. Participants must either be on stable antiretroviral therapy or have never been exposed to antiretroviral therapy for HIV infection.

What does the study involve?

HIV-positive patients attending clinics at Chris Hani Baragwanath Hospital, Soweto, South Africa and that can walk are randomly allocated to receive amitriptyline (25 mg) or a placebo for six weeks. The drug/placebo dose is increased every three days over the first two weeks of the treatment until participants achieve pain relief, intolerable side effects, or a maximum dose of 150 mg per day. The trial drug and the placebo are identical in appearance. Participants visit the study centre every three weeks to receive their medication and to record a pain score. At the end of the first six-week period, participants are taken off their assigned medication for a threeweek 'washout' period. After this washout period, those participants who receive amitriptyline before are now given the placebo and vice versa for another 6 weeks. Dose titration and pain assessments will follow the same protocol used in the first six-week period.

What are the possible benefits and risks of participating?

Some participants may achieve meaningful pain relief when receiving amitriptyline, a drug recommended as first-line therapy for other types of painful peripheral neuropathy. However, any positive results of this study will mostly benefit the large population of HIV-infected patients with painful peripheral neuropathy, for which there are no proven treatments. Risks of participating in the trial include side-effects of the medication, typically sedation, dry mouth and difficulty urinating.

Where is the study run from? Nthabiseng HIV Clinic and the Centre for Palliative Care, Chris Hani Baragwanath Hospital, Soweto, (South Africa)

When is the study starting and how long is it expected to run for? April 2009 to April 2010

Who is funding the study? The Diana Princess of Wales Memorial Fund (UK)

Who is the main contact? Dr Peter Kamerman peter.kamerman@wits.ac.za Dr Natalya Dinat natalyadinat5@gmail.com

Contact information

Type(s) Scientific

Contact name Dr Natalya Dinat

Contact details 86, 14th Street Parkhurst Johannesburg South Africa 2193

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

N/A

Double blind randomised controlled trial to assess the effectiveness of amitriptyline compared to placebo in the management of moderate to severe HIV related peripheral neuropathy.

Study objectives

Amitriptyline is superior to placebo in the management of moderate to severe HIV related peripheral neuropathy.

Ethics approval required Old ethics approval format

Ethics approval(s)

Human Research Ethics Committee, University of the Witwatersrand, South Africa, 16/09/2014, ref: M080709

Study design Placebo-controlled double-blind crossover group randomised controlled trial

Primary study design Interventional

Secondary study design Randomised cross over trial

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Pharmacological management of painful neuropathy

Interventions

All study participants will receive amitriptyline (titrated to efficacy, side effects or a maximum dose of 150 mg daily) or inert placebo in random order for 6 weeks, with a three-week washout period between interventions.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Amitriptyline

Primary outcome measure

Self-reported pain intensity, assessed on an 11-point numerical pain rating scale.

Secondary outcome measures

1. Pain interference on activities of daily living, assessed using the pain interference sub-scale of the Brief Pain Inventory

2. Physical symptoms, psychological, emotional and spiritual, and information and support needs, assessed using the African Palliative Care Outcomes Scale (APOS)

Primary and secondary outcomes were measured at baseline, three and six weeks for each of the two intervention periods. Across the duration of the study, that represents measurements at 0, 3, 6, 9, 12, and 15 weeks on each participant.

Overall study start date

01/04/2009

Completion date

30/04/2010

Eligibility

Key inclusion criteria

1. Confirmed and documented HIV positive status, either on Arv therapy or not on ARV therapy 2. Diagnosed with moderate to severe peripheral neuropathy using the BPNS and DN4 screening tools and scoring >/= 4 on an 11 point Likert scale visual analogue scale

3. Age above 18 on the date of recruitment

4. Ability to mentally and physically understand to make informed choice to participate in the study

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Sex Both

Target number of participants 124

Key exclusion criteria

All conditions which are likely to cause confounding will be excluded from the study, together with

conditions which are likely to cause drug interactions.

1. Severe pain from DSN caused by ARV drugs which warrants a change in regime

- 2. Already taking amitriptyline drug, or has taken the drugs at least three weeks prior
- 3. Limb amputation
- 4. Kaposi sarcoma of the lower limbs
- 5. Current post-herpetic neuralgia or herpes zoster
- 6. Pregnancy or intention to fall pregnant
- 7. TB treatment
- 8. Malignancy not related to HIV
- 9. Major psychiatric disorders including mania or epilepsy
- 10. Clinically significant renal failure
- 11. Diabetic neuropathy

12. Clinically significant liver failure or past history as defined by encephalopathy, oedema and jaundice

- 13. Patient in extreme pain or exhausted
- 14. Participating on another trial or study
- 15. MAOI, other tricyclic antidepressants or anti-epileptic drugs
- 16. Recent myocardial infarction, arrhythmias, heart block
- 17. History of urinary retention, urinary hesitancy or closed angle glaucoma

Date of first enrolment

01/04/2009

Date of final enrolment 30/04/2010

Locations

Countries of recruitment South Africa

Study participating centre 86, 14th Street Johannesburg South Africa 2193

Sponsor information

Organisation Diana Princess of Wales Memorial Fund (UK)

Sponsor details

The Royal Foundation of The Duke and Duchess of Cambridge and Prince Harry Kensington Palace Palace Green London United Kingdom W8 4PU

Sponsor type

Charity

Funder(s)

Funder type Charity

Funder Name

Diana Princess of Wales Memorial Fund (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	14/05/2015		Yes	No